Mostrar el registro sencillo del ítem
dc.contributor.author
Roberti, Maria Paula

dc.contributor.author
Arriaga, Juan Martín

dc.contributor.author
Bianchini, Michele

dc.contributor.author
Quintá, Héctor Ramiro

dc.contributor.author
Bravo, Alicia Ines

dc.contributor.author
Levy, Estrella Mariel

dc.contributor.author
Mordoh, Jose

dc.contributor.author
Barrio, Maria Marcela

dc.date.available
2025-02-14T12:53:34Z
dc.date.issued
2012-09
dc.identifier.citation
Roberti, Maria Paula; Arriaga, Juan Martín; Bianchini, Michele; Quintá, Héctor Ramiro; Bravo, Alicia Ines; et al.; Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice; Landes Bioscience; Cancer Biology & Therapy; 13; 11; 9-2012; 1123-1140
dc.identifier.issn
1538-4047
dc.identifier.uri
http://hdl.handle.net/11336/254437
dc.description.abstract
Triple negative breast cancers (TNBC) lacking hormone receptors and R-2 amplification are very aggressive tumors. Since relevant differences between primary tumors and metastases could arise during tumor progression as evidenced by phenotypic discordances reported for hormonal receptors or R-2 expression, in this analysis we studied changes that occurred in our TNBC model IIB-BR-G throughout the development of IIB-BR-G-MTS6 metastasis to the lymph nodes (LN) in nude mice, using an antibody-based protein array to characterize their expression profile. We also analyzed their growth kinetics, migration, invasiveness and cytoskeleton structure in vitro and in vivo. In vitro IIB-BR-G-MTS6 cells grew slower but showed higher anchorage independent growth. In vivo IIB-BR-G-MTS6 tumors grew significantly faster and showed a 100% incidence of LN metastasis after s.c. inoculation, although no metastasis was observed for IIB-BR-G. CCL3, IL1β, CXCL1, CSF2, CSF3, IGFB1, IL1α, IL6, IL8, CCL20, LUR, lGF and VGF were strongly upregulated in IIB-BR-G-MTS6 while CCL4, ICM3, CXCL12, TNFRSF18, FIGF were the most downregulated proteins in the metastatic cell line. IIB-BR-G-MTS6 protein expression profile could reflect a higher NFκB activation in these cells. In vitro, IIB-BR-G displayed higher migration but IIB-BR-G-MTS6 had more elevated matrigel invasion ability. In agreement with that observation, IIB-BR-G-MTS6 had an upregulated expression of MM1, MM9, MM13, LUR and GF. IIB-BR-G-MTS6 tumors presented also higher local lymphatic invasion than IIB-BR-G but similar lymphatic vessel densities. VGFC and VGF/B expression were higher both in vitro and in vivo for IIB-BR-G-MTS6. IIB-BR-G-MTS6 expressed more vimentin than IB-BR-G cells, which was mainly localized in the cellular extremities and both cell lines are -cadherin negative. Our results suggest that IIB-BR-G-MTS6 cells have acquired a pronounced epithelial-to-mesenchymal transition phenotype. rotein expression changes observed between primary tumor-derived IIB-BR-G and metastatic IIB-BR-G-MTS6 TNBC cells suggest potential targets involved in the control of metastasis.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Landes Bioscience

dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
Breast Cancer
dc.subject
Proteomics
dc.subject
Triple negative cancer
dc.subject.classification
Biología Celular, Microbiología

dc.subject.classification
Ciencias Biológicas

dc.subject.classification
CIENCIAS NATURALES Y EXACTAS

dc.title
Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2024-05-31T10:57:26Z
dc.journal.volume
13
dc.journal.number
11
dc.journal.pagination
1123-1140
dc.journal.pais
Estados Unidos

dc.journal.ciudad
Austin
dc.description.fil
Fil: Roberti, Maria Paula. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundación Cáncer. Centro de Investigaciones Oncológicas; Argentina
dc.description.fil
Fil: Arriaga, Juan Martín. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundación Cáncer. Centro de Investigaciones Oncológicas; Argentina
dc.description.fil
Fil: Bianchini, Michele. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundación Cáncer. Centro de Investigaciones Oncológicas; Argentina
dc.description.fil
Fil: Quintá, Héctor Ramiro. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; Argentina
dc.description.fil
Fil: Bravo, Alicia Ines. Gobierno de la Provincia de Buenos Aires. Hospital Interzonal de Agudos Evita; Argentina
dc.description.fil
Fil: Levy, Estrella Mariel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundación Cáncer. Centro de Investigaciones Oncológicas; Argentina
dc.description.fil
Fil: Mordoh, Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; Argentina. Fundación Cáncer. Centro de Investigaciones Oncológicas; Argentina
dc.description.fil
Fil: Barrio, Maria Marcela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundación Cáncer. Centro de Investigaciones Oncológicas; Argentina
dc.journal.title
Cancer Biology & Therapy

dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/abs/10.4161/cbt.21187
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.4161/cbt.21187
Archivos asociados